Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook

About this update from Enanta Pharmaceuticals, Inc.

WATERTOWN, Mass., January 08, 2026 --( BUSINESS WIRE )-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research and development programs and highlighted upcoming key milestones for 2026. "Building on the progress we achieved in our RSV and immunology portfolios this past year, we enter 2026 with strong momentum as we continue to expand our pipeline and deliver on key milestones," said Jay R. Luly, Ph.D., President and Chief Executive Officer at Enanta Pharmaceuticals. "We are eager to advance our RSV portfolio with the progression of both zelicapavir and EDP-323. We look forward to continuing our discussions with the FDA to align on an adult Phase 3 study design and solidify next steps for zelicapavir’s registration path. With positive data from both zelicapavir and EDP-323 in hand, we continue to have the leading portfolio of RSV therapeutics, offering broad optionality and the potential for first- and best-in-disease treatments." Dr. Luly continues, "Today, we are pleased to announce our third immunology program, focused on developing oral MRGPRX2 inhibitors for type 2 immune driven diseases, with an initial focus on CSU and other mast cell driven diseases, with other future expansion opportunities. MRGPRX2 signaling is a critical driver of inflammation, and inhibitors have the potential for strong efficacy with best-in-disease safety. This program represents a meaningful addition to our growing immunology portfolio, and we look forward to nominating a development candidate in the second half of 2026. In parallel, we are advancing EDP-978, our oral, once-daily KIT inhibitor clinical candidate with the goal of filing an IND in the first quarter and reporting Phase 1 data in the fourth quarter of this year. We are also progressing EPS-3903, our oral, once-daily STAT6 development candidate with plans to file an IND in the second half of 2026 and advance into the clinic shortly thereafter. With programs in KIT, STAT6 and MRGPRX2 inhibition, we are leveraging our proven expertise in small molecule drug discovery and development to build a leading immunology portfolio focused on type 2 immune driven diseases where there is a clear unmet need for convenient, safe and efficacious oral treatments. Finally, our strong cash position, with runway into fiscal 2029, provides us the resources to continue to build value by delivering highly differentiated therapeutics through innovative small molecule drug discovery." Pipeline Updates Virology Immunology Corporate The Company expects the following milestones across its pipeline in 2026: Webcast Information Enanta will provide further details on these updates at the 44 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:00 p.m. PT. A live webcast of the presentation will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta’s website at www.enanta.com . A replay of the webcast will be available following the presentation and will be archived for approximately 30 days. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT, STAT6 and MRGPRX2 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Forward Looking Statements This press release contains forward-looking statements, including statements with respect to the timeline and prospects for advancement of Enanta’s clinical programs in RSV and its preclinical immunology programs, including its programs targeting KIT, STAT6 and MRGPRX2 inhibition. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the impact of development, regulatory and marketing efforts of others with respect to vaccines and competitive treatments for RSV; the discovery and development risks of Enanta’s programs in virology and immunology; Enanta’s limited clinical development experience; Enanta’s ability to partner its RSV or other programs; Enanta’s need to attract and retain senior management and key research and development personnel; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in "Risk Factors" in Enanta’s Form 10-K for the fiscal year-ended September 30, 2025, and any other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260108666055/en/ Contacts Media and Investors Contact: Jennifer Viera 617-744-3848 [email protected]

View stock analysis, news, and events for Enanta Pharmaceuticals, Inc.